^
Association details:
| Biomarker: | RUNX1-RUNX1T1 fusion |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Mylotarg (gemtuzumab ozogamicin) (DNA replication inhibitor, CD33-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Excerpt:
Our recommendation is based primarily on the meta-analysis of five studies with GO, in which patients with CBF-AML (RUNX1-RUNX1T1- or CBFBMYH11-positive AML) benefit most from the addition of GO [GO improved 6-year overall survival (OS) by 20.7% to an OS of 75.5% in this meta-analysis].
DOI:
doi.org/10.1016/j.annonc.2020.02.018
